Table 1.
Demographic and clinical characteristics of the six study groups.
| HIV− | HIV+ | |||||
|---|---|---|---|---|---|---|
| Variable | Control (n=58) | Control (n=27) | Encoding II/Vis (n=30) | Monitoring STOP (n=30) | Cue Detect Tone (n=29) | Combination All (n=29) |
| Demographic | ||||||
| Age (yrs)* | 60.6 (7.6) | 57.9 (7.1) | 57.0 (7.0) | 58.6 (6.2) | 54.7 (4.0) | 57.2 (6.0) |
| Education (yrs) | 14.6 (2.5) | 13.3 (2.5) | 14.2 (2.7) | 14.8 (2.7) | 13.9 (2.9) | 14.0 (2.8) |
| Sex (% women)* | 34.5 | 11.1 | 20.0 | 16.7 | 13.8 | 10.3 |
| Ethn (% Hispanic) | 17.2 | 14.8 | 26.7 | 23.3 | 13.8 | 20.7 |
| Race (% White) | 65.5 | 79.3 | 63.0 | 62.1 | 66.7 | 66.7 |
| Psychiatric | ||||||
| Substance | 53.5 | 66.7 | 76.7 | 66.7 | 72.4 | 69.0 |
| Depression* | 32.8 | 74.1 | 76.7 | 66.7 | 69.0 | 62.1 |
| Anxiety* | 17.2 | 33.3 | 53.3 | 33.3 | 48.3 | 34.5 |
| Neurocognitive | ||||||
| Estimated VIQa | 110 (16) | 106 (15) | 105 (13) | 103 (14) | 106 (14) | 107 (16) |
| NCIb (%) | 24.1 | 38.5 | 37.9 | 50.0 | 22.2 | 14.8 |
| Medical | ||||||
| Comorbidities | 1.6 (1.4) | 2.3 (1.8) | 2.1 (1.4) | 2.2 (1.4) | 2.0 (1.5) | 2.4 (1.7) |
| HIV Disease | ||||||
| Duration (yrs) | ----- | 20.9 (8.22) | 21.3 (8.9) | 20.0 (8.9) | 21.7 (8.7) | 22.0 (8.4) |
| Nadir CD4 | ----- | 147 (132) | 174 (182) | 209 (1550 | 146 (151) | 260 (233) |
| Current CD4 | ----- | 582 (228) | 714 (349) | 711 (226) | 654 (264) | 694 (392) |
| AIDS | ----- | 76.9 | 73.3 | 56.7 | 65.5 | 65.5 |
| ART (%) | ----- | 96.0 | 90.0 | 93.1 | 100 | 82.8 |
| HIV RNA (%) | 4.1 | 0.0 | 7.14 | 11.5 | 0 | |
Note. AIDS = Acquired Immune Deficiency Syndrome; ART = antiretroviral therapy; Comorbidities refers to the number of medical diagnoses per the nursing evaluation (e.g., hypertension, diabetes, hepatitis C). Ethn = ethnicity; HIV = Human immunodeficiency virus; II/Vis = Implementation intentions and visualization; NCI = Neurocognitive impairment (per NIH Toolbox or CogState); STOP = Stop, Think, Organize, and Plan (i.e., context-free cueing)
n = 189.
n = 192.
p < .05